A mucosal vaccine prevents eosinophilic allergic airway inflammation by modulating immune responses to allergens in a murine model of airway disease

Carmen Sevilla-Ortega, Alba Angelina, Leticia Martín-Cruz, Mario Pérez-Diego, Angel Maldonado, Begoña Lavín, Beatriz Marcos-Ramiro, Luis Pérez de Llano, Auba Gayá, Francisco X. Real, Laura Conejero, José Luis Subiza and Oscar Palomares ()
Additional contact information
Carmen Sevilla-Ortega: Complutense University of Madrid
Alba Angelina: Complutense University of Madrid
Leticia Martín-Cruz: Complutense University of Madrid
Mario Pérez-Diego: Complutense University of Madrid
Angel Maldonado: Complutense University of Madrid
Begoña Lavín: Complutense University of Madrid
Beatriz Marcos-Ramiro: Complutense University of Madrid
Luis Pérez de Llano: Cervo
Auba Gayá: Centro Nacional de Investigaciones Oncológicas (CNIO)
Francisco X. Real: Centro Nacional de Investigaciones Oncológicas (CNIO)
Laura Conejero: Alcalá de Henares
José Luis Subiza: Alcalá de Henares
Oscar Palomares: Complutense University of Madrid

Nature Communications, 2025, vol. 16, issue 1, 1-18

Abstract: Abstract Allergic sensitization and viral infections are risk factors for asthma development and progression. Sublingual vaccination with MV130, a whole heat-inactivated polybacterial preparation, protects against viral infections, but its impact on allergic sensitization and asthma development remains unknown. Here we show MV130 prevents house dust mite (HDM)-induced local type 2 immune responses and associated eosinophilic airway inflammation, conferring protection up to 9 weeks after vaccination. MV130 reduces pathophysiological and clinical asthma features in an in vivo experimental mouse model of HDM-induced allergic eosinophilic asthma, restoring normal airway functionality. MV130 impairs allergen-specific IgE sensitization and systemic type 2 inflammation endorsing type 1 and IL-10 responses. In human DCs, MV130 induces a transcriptomic and metabolic reprogramming, and restores non-pathological immune responses to allergens in healthy and asthmatic donors. Additionally, the adoptive transfer of MV130-stimulated BMDCs was sufficient to reproduce the protective features of the vaccine administration in vivo. Collectively, we show MV130 reduces allergic sensitization and eosinophilic asthma. Our findings support the exploration of mucosal interventions aimed at reducing the risk of allergen-induced asthma development.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-62632-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-62632-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-62632-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().